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of scores was made. To illustrate,
according to Prinsen et al., the cutoff
scores for mildly, moderately, and
severely impaired HRQoL on the emo-
tions domain were X24, X35, and
X39, respectively, meaning that a
patient with a score X24 can be catego-
rized as having a mildly impaired HRQoL
on this domain, a score X35 as ‘‘mode-
rate’’, etc. However, Samponga and
Abeni categorized ‘‘mild’’ as having a
score between 0 and 23.9 and, as a
consequence, misclassified all cutoff
scores. Therefore, we would like to pro-
vide a correct overview of the categor-
ization of Skindex-29 scores (Table 1).
Having said this, we fully agree with
Sampogna and Abeni on the limitations
of both methods, such as dependence
on the distribution of HRQoL scores in
estimation samples and biases when
using prospective anchors. Neverthe-
less, we believe that, under the condi-
tion that the same scale or anchor
question is being used, anchor-based
methods may lead to less variant
estimates of cutoff scores than distribu-
tion-based methods. In addition, an-
chor-based methods are less dependent
on the sociocultural and clinical char-
acteristics of the estimation sample. For
example, patients in one sample, scor-
ing themselves as having a severely
impaired HRQoL on a global rating
scale or anchor question (for instance,
an anchor question such as ‘‘In your
opinion, how severe is your skin con-
dition?’’), are likely to have Skindex-29
scores in the same range of scores as
patients of another sample who also
score themselves as having a severely
impaired HRQoL. Nevertheless, the
phrasing of an anchor question is a
great source of variation in the compar-
ison of different cutoff scores. We
therefore advocate the use of standard-
ized anchors.
A clinically meaningful interpreta-
tion of Skindex-29 scores is of great
value. At present, two studies on this
intriguing subject are available. As
already expressed by Sampogna and
Abeni, the combination of an anchor-
based and a distribution-based method
in a subsequent study would allow an
objective comparison of the results
within one study population. In addi-
tion to this, we recommend including
standardized anchors, and to conduct
such a study on an international level.
Eventually, such efforts will contribute
to reaching consensus on the catego-
rization of scores so that they can be
applied in clinical practice.
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TO THE EDITOR
Any delay in wound closure increases
the probability of developing dermal
fibrotic conditions such as hypertrophic
scars (Deitch et al., 1983). For patients
with extensive burn injuries, one of
the most promising approaches is the
application of an engineered skin sub-
stitute containing both epidermal and
dermal cells (Coulomb et al., 1998).
Where allogeneic skin substitutes can
provide a rapid, patient-ready wound
coverage, they are susceptible to im-
mune rejection. Our approach has been
to engineer an allogeneic skin substituteAbbreviations: IDO, indoleamine 2,3-dioxygenase; SEI, scar elevation index
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Figure 1. Morphological and histological evaluation of skin substitutes in rabbit ear model. Skin substitutes containing indoleamine 2,3-dioxygenase
(IDO)-transduced (ESSIDO) and non-transduced (ESS) fibroblasts were applied on rabbit wounds. (a) Clinical appearance of wounds showed an increased
scar elevation in nontreated (NT) and ESS wounds compared with those of ESSIDO wounds, which showed a flatter scar (original magnification  2
bar¼ 1,000 mm). (b) Tissue samples were histologically analyzed for epidermal thickness (original magnification  40 bar¼ 40mm) and cellularity
(original magnification  60 bar¼ 10 mm) using hematoxylin and eosin staining (H&E). Normal rabbit skin was used as control (C). (c) Quantification and
statistical analysis was performed for scar elevation index (SEI), epidermal thickness, and cellularity. The results revealed a statistically significant decreased
SEI, epidermal thickness, and cellularity in ESSIDO samples compared with those of NT and ESS samples (*Po0.05 and **Po0.001).
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that expresses an immunomodulating
enzyme to protect the graft.
Indoleamine 2,3-dioxygenase (IDO)
is the rate-limiting enzyme of trypto-
phan catabolism that converts trypto-
phan to kynurenine (Taylor and Feng,
1991), and is well known to have a key
role in producing immunoprivileged
tissue environments. For example, it
has been shown that IDO has a role in
the prevention of the immune rejection
of the semi-allogeneic fetus (Munn
et al., 1998) and in the immune resis-
tance of tumors (Uyttenhove et al.,
2003). In our earlier work, we demon-
strated that the expression of IDO can
not only downregulate the expression
of MHC class I in IDO-transduced
keratinocytes (Li et al., 2004), but also
that it can prevent immune rejection of
grafted, simple xenogeneic fibroblast-
populated scaffolds (Li et al., 2006).
Conversely, depletion of tryptophan by
IDO jeopardizes the survival of CD4þ
lymphocytes and THP-1 monocytes
(Ghahary et al., 2004).
In this study, primary dermal fibro-
blasts were transduced with IDO gene
using a lentiviral vector (Rezakhanloo
et al., 2010). Kynurenine catabolite
concentration was found to be 36.5
times higher in conditioned media from
IDO-transduced cells compared with
controls (14.6±0.103 vs. 0.4±0.007,
n¼4; Po0.001). Bilayered skin sub-
stitutes were engineered to have both
an epidermal (primary keratinocytes)
and dermal layer containing either
IDO-transduced fibroblasts (ESSIDO)
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Figure 2. Molecular and histological characteristics of the tissue samples after 35 days post-transplantation. (a) Collagen and MMP-1 gene expression
in nontreated (NT), ESS, and ESSIDO tissue samples were evaluated. After 35 days, indoleamine 2,3-dioxygenase (IDO) was only expressed in the tissue
samples treated with ESSIDO (first row). A significant increase in MMP-1 expression was observed in ESSIDO-treated samples when compared with those
of control, NT, and ESS-treated samples (second row and graph). b-Actin was used as a loading control (fourth row; **Po0.001). (b) Tissue sections were
stained for HLA-DR (original magnification 10, bar¼ 100mm; and original magnification  40, bar¼ 100mm) and (c) CD3 (T-lymphocyte marker;
original magnification  10, bar¼ 100mm; and original magnification  60, bar¼ 50 mm). Only ESSIDO tissue samples showed the presence of HLA-DR;
moreover, ESSIDO sections revealed the presence of T cells only in the deep dermis. Arrows show positive cell staining.
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or non-transduced fibroblasts (ESS).
Using the rabbit ear model (Morris
et al., 1997), we created four 8-mm
punch wounds on the ventral surface of
each ear and either covered it with skin
substitutes or left it untreated (non-
treated (NT)). Wounds were evaluated
over a period of 35 days. Untreated
wounds were considered as the control
for wound healing progression. Clinical
and histological examination of the
wounds showed an increase in scar ele-
vation for NT and ESS wounds com-
pared with those of ESSIDO wounds,
which showed a flatter scar (Figure 1a).
Wounds were analyzed for epidermal
thickness and cellularity using hema-
toxylin and eosin staining. Normal
rabbit skin was used as control (C)
(Figure 1b top panel). Epidermal thick-
ness was found to be greater in NT
and ESS samples compared with that
of control and ESSIDO (Figure 1c). In
addition, both NT and ESS displayed
increased cellularity compared with
ESSIDO, which was more comparable
to normal skin (Figure 1b lower panel).
A decreased scar elevation index was
evident in ESSIDO wounds compared
with those of NT and ESS samples (1.4±
0.04 vs. 2.3±0.25 and 1.72±0.26,
respectively; n¼ 6; Po0.05). Moreover,
ESSIDO wounds showed a thinner
epidermal layer when compared with
those of ESS and NT wounds (1.99±
0.16 vs. 9.01±1.4 and 6.63±0.58,
respectively; n¼6, Po0.001). A signi-
ficant decrease in cellularity was also
found in the ESSIDO wounds com-
pared with either NT or ESS wounds
(108.25±5.34 vs. 238.88±24.01 and
164.30±4.68, respectively; n¼ 6,
Po0.001; Figure 1c). To further eluci-
date the role that ESSIDO might have in
mitigating fibrotic conditions, biopsies
were examined for MMP-1 and pro-a1
collagen messenger RNA. At the gene
level, we found that MMP-1 expres-
sion in the ESSIDO-treated wounds
was significantly higher compared
with control, NT, and ESS-treated
wounds (1.21±0.06 vs. 0.38±0.16,
0.13±0.15, and 0.73±0.03, respec-
tively; n¼3, Po0.001; Figure 2a). In
contrast, there was no significant differ-
ence in pro-a1 collagen gene expres-
sion. Therefore, these data suggest
that local IDO expression in vivo is
correlated with an increase in MMP-1,
without changing the production of
collagen (pro-a1). To ensure that grafted
cells were present in the rabbit tissue
for 35 days, biopsy sections were
stained with a mAb for HLA-DR, revea-
ling the presence of human keratino-
cytes from the ESSIDO in rabbit tissue
but not in those from NT or ESS tissue
samples (Figure 2b). In comparison,
wound sections were also stained with
a CD3 lymphocyte mAb demonstrat-
ing a random distribution of T cells
throughout the dermis of both NT and
ESS. Interestingly, ESSIDO-treated tis-
sue sections were infiltrated with fewer
T cells, present only in the deep dermis
and as if to form a linear distribution
(Figure 2c). These results suggest that
the expression of IDO by the ESSIDO
creates a barrier-impeding migration of
T cells into the transplanted graft.
Using a well-documented rabbit ear
fibrotic model, we showed that the
application of a skin substitute contain-
ing IDO-transduced cells improves scar
elevation, epidermal thickness, and
cellularity, which are the known char-
acteristics of dermal fibroproliferative
disorders. In addition, we demonstrated
that IDO-expressing cells significantly
stimulated MMP-1 expression in bystan-
der fibroblasts (Supplementary Figure S1
online). This finding suggests that IDO
likely induces MMP-1 expression in the
host fibroblasts. Although it remains to
be further elucidated, the mechanism
for this response could be partly due to
depletion of tryptophan or an increase
in IDO metabolites. Again, we are able
to demonstrate that IDO is able to protect
a multicellular xenograft from rejection,
similar to our previous study (Jalili et al.,
2010). CD3 staining in the ESSIDO samples
revealed the presence of these cells only
in the deep dermis, corresponding with
our previous in vitro findings (Forouzandeh
et al., 2008) and suggesting that the
IDO may create a niche that restricts
T-cell infiltration.
In conclusion, this study describes a
possible alternative role for IDO in scar
improvement through MMP-1 stimula-
tion in host cells. Moreover, it demon-
strates the survival of an ESSIDO graft
for up to 35 days, (Supplementary
Figures S2, S3 online) suggesting the
possibility of serving as a permanent
wound coverage. Further studies are
suggested to address the mechanism
through which these phenomena occur.
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Validation of GWAS Loci for Atopic Dermatitis
in a Singapore Chinese Population
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TO THE EDITOR
Atopic dermatitis (AD) is a complex
trait resulting from an interaction be-
tween a large variety of environmental
and genetic factors (Irvine and McLean,
2006; Rodrı´guez et al., 2009; van den
Oord and Sheikh, 2009). Research
on the filaggrin gene (FLG) in Asian
populations including Singapore has
confirmed that allelic variants in this
gene influence risk to AD (Akiyama,
2010), as in Europe, while also strength-
ening the evidence for other factors
involved in the disease etiology (Chen
et al., 2011). Recently, Sun et al. (2011)
reported a genome-wide association
study on AD in which they identified
two new susceptibility loci at 5q22.1
(rs7701890) and 20q13.33 (rs6010620),
and one suggestive locus at 10q21.2
(rs2393903) in the Chinese population.
The previously unreported associations
were validated in Northern and South-
ern Chinese, but only the 20q13.33
(rs6010620) locus was validated in a
German population, supporting the pre-
sence of ethnic differences or environ-
mental influences on the observed
genetic associations.
Here, we analyzed these three loci
in 827 AD cases and 1,104 controls
(Supplementary Information online),
all of which were Singaporean Chinese
(Andiappan et al., 2011). All three
single-nucleotide polymorphisms (SNPs)
were directly assayed by Taqman geno-
typing and were found to be in Hardy–
Weinberg equilibrium in controls
(P40.05). The chromosome (chr)10
and chr20 SNPs showed significant
association in our population (odds
ratio (OR)¼ 1.26 (95% confidence
interval (CI) 1.11–1.44), P¼0.0004;
and OR¼ 1.18 (95% CI 1.02–1.36),
P¼0.024, respectively). The effect sizes
of these associations are similar to that
reported in Sun et al. (Table 1). How-
ever, the chr5 SNP rs7701890 showed
no evidence of association (OR¼0.96
(95% CI 0.81–1.13), P¼0.59). With
our current sample size and the minor
allele frequency of 20% in Singaporean
Chinese, we estimate that we had close
to 80% power to detect the effect
observed by Sun et al. (OR 1.24; Purcell
et al., 2003).
The well-known association of atopy
with allergic phenotypes (Bousquet
et al., 2001, 2008) prompted us to
investigate the association of the three
SNPs with positive skin prick test (SPT)
results in our cohort. We analyzed
a total of 2,627 SPT-positive and
389 SPT-negative individuals, which
included both AD cases and controls.
There was no association with positive
SPT status (Supplementary Table S1
online), and adjustment for this SPT
status had little or no impact on the
AD association results for the chr10 and
chr20 SNPs. We then tested the three
above-mentioned SNPs (rs7701890,
rs2393903, and rs6010620) for associa-
tion with allergic rhinitis (AR; 472
cases) and asthma (323 cases), in the
absence of AD. The rs6010620 SNP
on 20q13.33 was associated with AR
(P¼0.008), although further validation
of this result is required. Although
the 5q22.1 locus has recently been
reported to be associated with AR
(Ramasamy et al., 2011), the SNP we
tested was not in linkage disequilibrium
with any of the reported SNPs (r2¼ 0
with rs17513503 and rs1898671).
The AD cases were separated into
two groups (i) AD only and (ii) AD with
other associated atopic conditions
(asthma, AR, or both). We found the
risk C allele of the chr10 locus showed
a significantly stronger association
with the group with AD only compared
with the group with AD and other
atopic conditions (OR¼ 1.45 (95% CI
1.21–1.79) vs 1.19 (1.03–1.38), P¼
0.038; Table 1). We then performed a
quantitative trait analysis in a subset of
397 AD cases whose disease seve-
rities were determined by the SCORing
Atopic Dermatitis (SCORAD) index
(Oranje et al., 2007). Consistently, we
found the CC genotype of rs2393903
at chr10 was significantly associated
with a lower SCORAD score (mean
33.99±1.568; n¼94), compared with
Abbreviations: AD, atopic dermatitis; AR, allergic rhinitis; CI, confidence interval; OR, odds ratio;
SCORAD, SCORing Atopic Dermatitis; SNP, single-nucleotide polymorphism; SPT, skin prick test
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